| Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis (NCT05733897) | National Taiwan University Hospital | 2022-06-10 |
| A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH (NCT03970031) | Cirius Therapeutics, Inc. | 2022-06-01 |
| Metabolic Pathology of Pediatric NAFLD (NCT05430178) | University of Oklahoma | 2022-05-25 |
| Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study (NCT05309642) | Ewha Womans University Mokdong Hospital | 2022-03-07 |
| Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease (NCT05330923) | Peking Union Medical College Hospital | 2022-01-01 |
| Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease (NCT05084404) | Yokohama City University | 2021-10-29 |
| Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis (NCT05011305) | Zydus Therapeutics Inc. | 2021-08-18 |
| Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (NCT04971785) | Gilead Sciences | 2021-08-09 |
| A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) (NCT04944992) | Merck Sharp & Dohme LLC | 2021-08-04 |
| FTIH Study of ECC0509 in Healthy Volunteers (NCT05012423) | Eccogene | 2021-07-26 |
| FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis (NCT04710524) | Future Medicine | 2021-06-10 |
| Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study (NCT04550481) | Northwestern University | 2021-05-11 |
| First-in-Human Study of SRT-015 in Healthy Subjects. (NCT04887038) | Syneos Health | 2021-05-03 |
| Noninvasive Biomarkers of Metabolic Liver Disease 1.1 (NCT04828551) | Massachusetts General Hospital | 2021-03-18 |
| CM-101 in NASH Patients - The SPLASH Study (NCT05824156) | ChemomAb Ltd. | 2021-02-24 |
| Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes (NCT04595474) | Joslin Diabetes Center | 2021-01-14 |
| Low-Dose Pioglitazone in Patients With NASH (AIM 2) (NCT04501406) | University of Florida | 2020-12-15 |
| A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (NCT04583423) | Merck Sharp & Dohme LLC | 2020-11-11 |
| ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability (NCT04561245) | Altimmune, Inc. | 2020-11-10 |
| A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) (NCT04565717) | Alnylam Pharmaceuticals | 2020-10-09 |
| Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis (NCT04399538) | Pfizer | 2020-08-10 |
| Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH) (NCT04147195) | Novartis Pharmaceuticals | 2020-06-04 |
| Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH) (NCT04216693) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2020-06-01 |
| To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants (NCT04389775) | Sciwind Biosciences APAC CO Pty. Ltd. | 2020-03-29 |
| Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) (NCT04210245) | NGM Biopharmaceuticals, Inc | 2020-03-23 |
| Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease (NCT04235205) | Yokohama City University | 2020-01-29 |
| Safety and Tolerability of Oral Proglumide for NASH (NCT04152473) | Georgetown University | 2019-12-13 |
| A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH (NCT04342793) | AngioLab, Inc. | 2019-12-04 |
| A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) (NCT04166773) | Eli Lilly and Company | 2019-11-19 |
| Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease (NCT04031729) | Massachusetts General Hospital | 2019-09-12 |
| Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) (NCT03987074) | Gilead Sciences | 2019-07-29 |
| Norursodeoxycholic Acid vs. Placebo in NASH (NCT05083390) | Dr. Falk Pharma GmbH | 2019-07-08 |
| Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study (NCT04012242) | Tokyo Medical University | 2019-06-15 |
| Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference (NCT04389593) | University of California, San Diego | 2019-05-21 |
| Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of NASH (NCT05343780) | Natural Wellness Egypt | 2019-05-08 |
| Dapagliflozin Efficacy and Action in NASH (NCT03723252) | Nanfang Hospital, Southern Medical University | 2019-03-20 |
| De Novo Lipogenesis in Severity of NAFLD (NCT03683589) | University of Missouri-Columbia | 2019-02-01 |
| Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance (NCT05165706) | Stanford University | 2019-01-31 |
| Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH) (NCT03676231) | Second Genome | 2019-01-18 |
| A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) (NCT03656744) | HighTide Biopharma Pty Ltd | 2018-11-26 |
| An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function (NCT03674476) | Bristol-Myers Squibb | 2018-09-11 |
| A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (NCT03486899) | Bristol-Myers Squibb | 2018-06-19 |
| A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis (NCT03486912) | Bristol-Myers Squibb | 2018-06-12 |
| Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese (NCT03282305) | Great China Fatty Liver Consortium Limited | 2018-04-01 |
| Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (NCT03449446) | Gilead Sciences | 2018-03-21 |
| A Study of Experimental Medication BMS-986036 Given to Healthy Participants (NCT03445208) | Bristol-Myers Squibb | 2018-02-14 |
| Feasibility of VIIT in Adults With NASH (NCT03861819) | Duke University | 2018-01-01 |
| Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH (NCT03332940) | Navidea Biopharmaceuticals | 2017-12-06 |
| A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis (NCT03329885) | Bristol-Myers Squibb | 2017-11-02 |
| Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NCT03439254) | Intercept Pharmaceuticals | 2017-08-30 |
| Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) (NCT03248882) | Pfizer | 2017-08-22 |
| The Liver Health Study for Patients with NAFLD (NCT03151798) | University of Missouri-Columbia | 2017-08-09 |
| Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis (NCT03061721) | Zydus Therapeutics Inc. | 2017-04-06 |
| AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) (NCT03028740) | Tobira Therapeutics, Inc. | 2017-04-05 |
| Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis (NCT03059446) | Tobira Therapeutics, Inc. | 2017-02-14 |
| Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (NCT03053050) | Gilead Sciences | 2017-02-13 |
| A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH) (NCT03163810) | Erchonia Corporation | 2017-02-06 |
| Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (NCT03053063) | Gilead Sciences | 2017-01-30 |
| A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes (NCT03068078) | Odense University Hospital | 2016-11-01 |
| A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes (NCT02769091) | Teva Branded Pharmaceutical Products R&D, Inc. | 2016-09-30 |
| Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD (NCT03725631) | Korea University Guro Hospital | 2016-09-01 |
| A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) (NCT02815891) | Target PharmaSolutions, Inc. | 2016-07-01 |
| Pathogenesis of Non-alcoholic Steatohepatitis and Liver Regeneration After Bariatric Surgery (NCT02792634) | RWTH Aachen University | 2016-06-01 |
| Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers (NCT05983328) | Sinew Pharma Inc. | 2016-05-10 |
| NASH: Non-invasive Diagnostic Markers and Imaging (NCT02717000) | Maastricht University Medical Center | 2016-04-01 |
| Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) (NCT02633956) | Intercept Pharmaceuticals | 2015-12-04 |
| Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis (NCT02510599) | Melinta Therapeutics, Inc. | 2015-12-01 |
| A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis (NCT02574325) | Arisaph Pharmaceuticals Inc | 2015-10-01 |
| CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy (NCT02654977) | University of Michigan | 2015-09-29 |
| Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis (NCT02421094) | Galectin Therapeutics Inc. | 2015-09-01 |
| JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NCT02442687) | Manal Abdelmalek | 2015-08-01 |
| Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH (NCT02412540) | Children's Hospital Medical Center, Cincinnati | 2015-04-23 |
| Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients (NCT02210715) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2015-03-01 |
| Probiotics in the Treatment of NAFLD (NCT02764047) | Federal University of Health Science of Porto Alegre | 2015-01-01 |
| Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis (NCT02307344) | Hillel Yaffe Medical Center | 2015-01-01 |
| Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis (NCT02217475) | Tobira Therapeutics, Inc. | 2014-09-18 |
| A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases (NCT02077374) | Conatus Pharmaceuticals Inc. | 2014-03-01 |
| Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS) (NCT01919294) | Sheffield Teaching Hospitals NHS Foundation Trust | 2013-07-01 |
| Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease (NCT01828528) | Sheba Medical Center | 2013-04-01 |
| Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients (NCT04462081) | University of California, San Diego | 2013-01-01 |
| Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome (NCT02083367) | OSF Healthcare System | 2013-01-01 |
| Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis (NCT01466894) | Immuron Ltd. | 2012-12-01 |
| Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy (NCT01679197) | University of Michigan | 2012-10-08 |
| Anti-Fibrotic Effects of Losartan In Nash Evaluation Study (NCT01051219) | Newcastle-upon-Tyne Hospitals NHS Trust | 2011-05-01 |
| Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes (NCT01399645) | Centre hospitalier de l'Université de Montréal (CHUM) | 2011-05-01 |
| Rifaximin in Fatty Liver Disease (NCT01355575) | Imperial College London | 2011-05-01 |
| Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes (NCT01260246) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2010-12-01 |
| Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis (NCT01094158) | Galmed Medical Reserch | 2010-11-01 |
| Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome (NCT01205087) | Hadassah Medical Organization | 2010-09-01 |
| Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis (NCT01237119) | University of Birmingham | 2010-08-01 |
| Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment (NCT01002547) | VA Office of Research and Development | 2010-06-24 |
| Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis (NCT01066364) | University of California, San Diego | 2010-02-01 |
| Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease (NCT01016418) | Hadassah Medical Organization | 2010-01-01 |
| Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis (NCT00820651) | Catalysis SL | 2009-11-01 |
| University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) (NCT00994682) | University of Florida | 2008-12-01 |
| Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH) (NCT00740610) | Gilead Sciences | 2008-08-01 |
| Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH) (NCT00699036) | Brooke Army Medical Center | 2007-04-01 |
| Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis (NCT00509418) | Catalysis SL | 2007-02-01 |
| Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection (NCT00842205) | Charles University, Czech Republic | 2007-01-01 |
| Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.) (NCT00586313) | Indiana University | 2007-01-01 |